FDA Approves Acquired Hemophilia Drug

Yesterday the Food and Drug Administration (FDA) approved medication for a rare factor deficiency called acquired hemophilia A.  The pharmaceutical, called Obizur, is manufactured by the Baxter Healthcare Corporation.

According to FDA.gov,  acquired hemophilia A is a rare, but potentially life threatening, bleeding disorder caused by the development of antibodies (immune system proteins) directed against the body’s own FVIII, a protein important for blood clotting. It is not a genetic disorder, affecting both males and females, and the diagnosis of this condition can be difficult – severity of the bleeding can make treatment challenging.

“The approval of this product provides an important therapeutic option for use in the care of patients with this rare disease,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research.

More information concerning availability will be posted as it becomes available.

Photo Credit – Food and Drug Administration (FDA)/ Baxter Healthcare Corporation

webleed.org – your source for bleeding news!